This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
by Zacks Equity Research
Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Esperion (ESPR) Aims to Expand Key Drug Labels for Growth
by Zacks Equity Research
Esperion's (ESPR) non-statin approved drugs uptake has continued to be the growth driver since launch. However, the company is currently facing a conflict with its partner, Daiichi Sankyo, regarding milestone payments.
J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer
by Zacks Equity Research
J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.
What Makes ANI (ANIP) a New Strong Buy Stock
by Zacks Equity Research
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for August 25th
by Zacks Equity Research
ANIP, AZPN and EXTR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25, 2023.
Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio
by Zacks Equity Research
Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.
New Strong Buy Stocks for August 25th
by Zacks Equity Research
ANIP, NVMI, AZPN, GRNT and CVLG have been added to the Zacks Rank #1 (Strong Buy) List on August 25, 2023.
Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate
by Zacks Equity Research
Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.
Humana (HUM) to Bring Enhanced Kidney Care to MA Members
by Zacks Equity Research
Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
by Zacks Equity Research
Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.
Here's Why Momentum in ANI (ANIP) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI (ANIP) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ANI Pharmaceuticals (ANIP) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 100% and 20.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -248.78% and 88.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.
ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed the most recent trading day at $52.79, moving +1.15% from the previous trading session.
ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed the most recent trading day at $51.89, moving +1.07% from the previous trading session.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and ImmunoGen (IMGN) have performed compared to their sector so far this year.
ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $51.30, marking a +0.33% move from the previous day.
Ensign Group (ENSG) Up 26% in a Year: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.
GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.